Focus topics


The diluted mRNA triumph

News of the approval of a Chinese mRNA vaccine in Indonesia came as something of a surprise last week. It is unclear why Indonesia is rushing ahead with approval while trials are still ongoing. Vaccines, after all, are no longer in short supply. What is clear now, however, is that AWcorna is expected to be the first Chinese mRNA drug that will also soon be officially ready for approval.

Continue reading now

Get 30 days of free access to the Professional Briefing to read these and more quality news every day.

Are you already a guest at the China.Table? Log in now

Related

    ‘Turning away from China would come at a high price’
    Tianjin becomes pioneer in port digitization
    Habeck forges own China strategy
    Michel and Xi talk past each other